JP2009542602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542602A5 JP2009542602A5 JP2009517275A JP2009517275A JP2009542602A5 JP 2009542602 A5 JP2009542602 A5 JP 2009542602A5 JP 2009517275 A JP2009517275 A JP 2009517275A JP 2009517275 A JP2009517275 A JP 2009517275A JP 2009542602 A5 JP2009542602 A5 JP 2009542602A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- derivative according
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- UIOQKSSBVKFEDS-UHFFFAOYSA-N 1,3-bis(phenylmethoxymethyl)benzimidazol-2-imine Chemical compound C12=CC=CC=C2N(COCC=2C=CC=CC=2)C(=N)N1COCC1=CC=CC=C1 UIOQKSSBVKFEDS-UHFFFAOYSA-N 0.000 claims 1
- MARQDIYHSBYEGG-UHFFFAOYSA-N 1,3-bis[(4-chlorophenoxy)methyl]benzimidazol-2-imine Chemical compound C1=CC(Cl)=CC=C1OCN1C(=N)N(COC=2C=CC(Cl)=CC=2)C2=CC=CC=C21 MARQDIYHSBYEGG-UHFFFAOYSA-N 0.000 claims 1
- LCWKPCRDQLAEHD-UHFFFAOYSA-N 1,3-bis[(4-chlorophenyl)sulfanylmethyl]benzimidazol-2-imine Chemical compound C1=CC(Cl)=CC=C1SCN1C(=N)N(CSC=2C=CC(Cl)=CC=2)C2=CC=CC=C21 LCWKPCRDQLAEHD-UHFFFAOYSA-N 0.000 claims 1
- XHUSPMDZOBCQOM-UHFFFAOYSA-N 1,3-bis[2-(4-fluorophenoxy)ethyl]benzimidazol-2-imine Chemical compound C1=CC(F)=CC=C1OCCN1C(=N)N(CCOC=2C=CC(F)=CC=2)C2=CC=CC=C21 XHUSPMDZOBCQOM-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- -1 [2- (4-fluorophenoxy) ethyl]-{1- [2- (4-fluorophenoxy) ethyl] -1H-benzimidazol-2-yl} amine Chemical class 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81884106P | 2006-07-07 | 2006-07-07 | |
| DKPA200600944 | 2006-07-07 | ||
| PCT/EP2007/056826 WO2008003752A1 (en) | 2006-07-07 | 2007-07-05 | 2 -amino benzimidazole derivatives and their use as modulators of small - conductance calcium -act ivated potassium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542602A JP2009542602A (ja) | 2009-12-03 |
| JP2009542602A5 true JP2009542602A5 (OSRAM) | 2010-07-15 |
Family
ID=38543613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009517275A Abandoned JP2009542602A (ja) | 2006-07-07 | 2007-07-05 | ２−アミノベンズイミダゾール誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルの調節剤としてのそれらの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100035951A1 (OSRAM) |
| EP (1) | EP2041096A1 (OSRAM) |
| JP (1) | JP2009542602A (OSRAM) |
| WO (1) | WO2008003752A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010015037A1 (en) * | 2008-08-08 | 2010-02-11 | Howard Florey Institute | Therapeutic methods and compositions |
| CN102947275A (zh) * | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
| EP2582680A1 (en) * | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| CN104744375B (zh) * | 2015-02-10 | 2017-09-19 | 南开大学 | 一种胍类ntr1小分子拮抗剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981886A (en) * | 1975-01-20 | 1976-09-21 | E. R. Squibb & Sons, Inc. | Amino-benzimidazole derivatives |
| US4004016A (en) * | 1975-08-11 | 1977-01-18 | E. R. Squibb & Sons, Inc. | Amino-benzimidazole derivatives |
| WO2000001676A1 (en) * | 1998-07-02 | 2000-01-13 | Neurosearch A/S | Potassium channel blocking agents |
| EP1838306B1 (en) * | 2005-01-11 | 2010-11-17 | NeuroSearch A/S | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| JP4751435B2 (ja) * | 2008-10-09 | 2011-08-17 | 株式会社東芝 | モータ磁極位置検出装置，モータ制御装置，モータ駆動システム及び洗濯機 |
-
2007
- 2007-07-05 WO PCT/EP2007/056826 patent/WO2008003752A1/en not_active Ceased
- 2007-07-05 US US12/307,083 patent/US20100035951A1/en not_active Abandoned
- 2007-07-05 JP JP2009517275A patent/JP2009542602A/ja not_active Abandoned
- 2007-07-05 EP EP07787116A patent/EP2041096A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526815A5 (OSRAM) | ||
| CN101103034A (zh) | 抑制β-分泌酶的氨基-咪唑酮 | |
| JP2007509043A5 (OSRAM) | ||
| JP2009519995A5 (OSRAM) | ||
| JP2002531552A5 (OSRAM) | ||
| JP5490100B2 (ja) | ５−（２−アミノ−ピリミジン−４−イル）−２−アリール−ｌＨ−ピロール−３−カルボキサミドの製造方法 | |
| JP2009542602A5 (OSRAM) | ||
| JP2020535168A5 (OSRAM) | ||
| JP2008546639A5 (OSRAM) | ||
| CN1202168A (zh) | 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物 | |
| JP2009024025A (ja) | テモゾロミドおよびアナログの合成 | |
| CN104470913B (zh) | 用于制造羟基化的环戊基嘧啶化合物的方法 | |
| JP2008543915A5 (OSRAM) | ||
| JP4796046B2 (ja) | ピペリジニルアルキルカーバメートの誘導体、これらの製造方法及びｆａａｈ酵素インヒビターとしての使用 | |
| IL235097A (en) | History of insulin-2 and as protein kinase inhibitors | |
| US20110003862A1 (en) | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | |
| CN1458933A (zh) | 噻吩并嘧啶化合物及其盐以及其制备方法 | |
| JP2010502674A5 (OSRAM) | ||
| CN101356160A (zh) | 作为辣椒素受体拮抗剂的三取代的喹唑啉酮衍生物 | |
| JP2009530352A5 (OSRAM) | ||
| CN1288153C (zh) | 2－氨基－4－吡啶基甲基－二氢噻唑衍生物作为诱导型no－合酶抑制剂的用途 | |
| JP2010509249A5 (OSRAM) | ||
| JP2009511548A5 (OSRAM) | ||
| CN1261414C (zh) | 作为单胺氧化酶(mao－b)抑制剂的吡啶酰氨基衍生物 | |
| JP2009518359A5 (OSRAM) |